Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESCUE-ALS: CNM-Au8 in early symptomatic ALS
NCT04098406Phase 2Completed
- Sponsor
- Clene Inc.
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CNM-Au8 in amyotrophic lateral sclerosis (ALS), sponsored by Clene Inc.. Started Dec 2019; status: completed.
02
Drugs
CNM-Au8
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04098406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04098406.